Skip to content
Tuesday 18 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,728.04
+0.07%
DAX
26,128.36
-0.80%
CAC 40
8,509.36
-0.82%
STOXX 50
6,468.17
-0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 19 March 2020 4:32 pm

Coronavirus: US looks to approve new treatments as cases pass 10,000

By: Edward Thicknesse

Add as a preferred source on Google
asian stocks

US president Donald Trump has announced that anti-malaria drug hydroxychloroquine will be made available almost immediately to treat coronavirus, as the number of cases in the US passed 10,000. 

The drug is one of a number of therapies that the US Food and Drug Administration (FDA) is investigating as possible treatments for the virus.

Trump said that the treatment could be a “game-changer” in the fight against coronavirus, and hailed the work being done by the FDA to combat the disease:

“For the FDA to act so fast is an incredible thing… it’s a very exciting time for medicine”, he said. 

The White House’s coronavirus task force coordinator Dr Deborah Birx said that 10 per cent of tests for the virus were coming back positive.

She added that 50 per cent of all cases in the US came from just 10 counties. 

US authorities have been focused on amping up the number of tests conducted, with New York governor Andrew Cuomo saying the state tested nearly 8,000 people overnight.

Read more

As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.

Sign up to Morning Wire’s Midday Update newsletter, delivered to your inbox every lunchtime

In a wide-ranging press conference, the president said that the virus was “too bad, because we have never had an economy as we had a few weeks ago”.

He was, however, bullish on the future of the economy, saying that it would “be back”:

“It’s going to go up very rapidly [once the crisis is over]… back to where we were and beyond”. 

Trump also highlighted his role in pulling together an emergency aid package for workers and business, saying that he had “slashed red tape like never before” to get the measures in place.

Despite hailing the bipartisan spirit on Capitol Hill, he could not resist another jibe at the expense of China, saying:

“If people had known about [the disease], it could have been stopped where it came from… China”.

Read more

As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

Donald Trump speaking at a podium, microphone visible, discussing the Strait of Hormuz

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Related Topics

  • Coronavirus
  • International

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • US bond market jitters spark UK economy recession warning

  • Monzo chair makes early exit after boardroom rift

  • Aldi boss wades into supermarket ‘price-gouging’ row

More from Morning Wire

  • As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

    Markets
    Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.
  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

    FTSE 100 Live
    Donald Trump speaking at a podium, microphone visible, discussing the Strait of Hormuz
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Trump and Infantino: The venomous relationship between sport and politics

    Sport Business
    GettyImages 2250174638 likely features a relevant business scene or newsworthy event, fitting for a general news article c...
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook